We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+29.85%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3.09B
AUM Growth
+$304M
Cap. Flow
-$377M
Cap. Flow %
-12.21%
Top 10 Hldgs %
47.14%
Holding
153
New
43
Increased
25
Reduced
27
Closed
29

Top Buys

Rank Stock Value
1
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$99.9M
2
ABBV icon
AbbVie
ABBV
+$92.7M
3
LRMR icon
Larimar Therapeutics
LRMR
+$41.5M
4
WBA
Walgreens Boots Alliance
WBA
+$40.8M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$36.4M

Top Sells

Rank Stock Value
1
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$216M
2
AGN
Allergan Inc
AGN
+$129M
3
RNA
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
+$62.2M
4
NVRO
NEVRO CORP.
NVRO
+$40.5M
5
AERI
Aerie Pharmaceuticals
AERI
+$36.3M

Sector Composition

Rank Sector Weight
1 Healthcare 60.38%
2 Financials 2.52%
3 Technology 0.47%
4 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRIV
51
DELISTED
TRIVASCULAR TECHONOLOGIES, INC, COMMON STOCK
TRIV
$10.4M 0.34%
990,202
-158,373
-14% -$1.63M
EXEL icon
52
PUT
Exelixis
EXEL
$14.1B
$10.3M 0.33%
+4,000,000
New +$9.28M
GEN
53
DELISTED
Genesis Healthcare, Inc.
GEN
$10.2M 0.33%
+1,432,368
New +$10.8M
GNCA
54
DELISTED
Genocea Biosciences, Inc.
GNCA
$10M 0.32%
105,532
+30,000
+40% +$2.12M
ADPT
55
DELISTED
Adeptus Health Inc
ADPT
$9.97M 0.32%
198,600
+135,547
+215% +$5.36M
KERX
56
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$9.74M 0.32%
765,450
-418,034
-35% -$5.37M
IMMU
57
DELISTED
Immunomedics Inc
IMMU
$9.6M 0.31%
2,505,972
-300,000
-11% -$1.3M
TNXP icon
58
Tonix Pharmaceuticals
TNXP
$198M
– –
0
– –
RIGL icon
59
Rigel Pharmaceuticals
RIGL
$750M
$8.56M 0.28%
239,786
– –
DSCI
60
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$8.39M 0.27%
991,040
+269,494
+37% +$2.3M
ARCT icon
61
Arcturus Therapeutics
ARCT
$172M
$7.96M 0.26%
+201,887
New +$8.88M
ELOS
62
DELISTED
Syneron Medical Ltd
ELOS
$7.75M 0.25%
+625,593
New +$6.93M
OXFD
63
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$7.35M 0.24%
+522,250
New +$7.11M
ATEC icon
64
Alphatec Holdings
ATEC
$1.31B
$7.22M 0.23%
415,228
+83,333
+25% +$1.39M
DBVT
65
DBV Technologies
DBVT
$870M
$6.96M 0.23%
29,812
-18,418
-38% -$4.37M
TCON
66
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$6.81M 0.22%
+2,425
New +$6.37M
AMPH icon
67
Amphastar Pharmaceuticals
AMPH
$871M
$6.71M 0.22%
448,532
-828,045
-65% -$11.1M
STRM
68
DELISTED
Streamline Health Solutions
STRM
$6.47M 0.21%
121,517
– –
FOMX
69
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$6.29M 0.2%
679,627
-65,172
-9% -$583K
ARAV
70
DELISTED
Aravive, Inc. Common Stock
ARAV
$6.24M 0.2%
+56,617
New +$6.64M
ZSPH
71
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$6.2M 0.2%
+147,385
New +$6.74M
BEAT
72
DELISTED
BioTelemetry, Inc.
BEAT
$5.7M 0.18%
644,300
+215,300
+50% +$2.18M
CLLS
73
Cellectis
CLLS
$265M
$5.2M 0.17%
+150,506
New +$5.46M
LMNS
74
DELISTED
LUMENIS LTD CL B ORD SHS (ISR)
LMNS
$5.2M 0.17%
434,566
-163,300
-27% -$1.77M
TVRD
75
Tvardi Therapeutics
TVRD
$30M
$4.76M 0.15%
13,155
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q1 2015 Portfolio in Review

As of Q1 2015, Deerfield Management held 153 positions worth $3.09B, up 11% from $2.78B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Deerfield Management withdrew a net $377M in Q1 2015, closing 29 positions and reducing 27 holdings. Its most notable exit was AUXILIUM PHARAMCEUTICALS INC, an estimated $216M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 52% a quarter earlier, followed by Financials and Technology.

Against the trend, Deerfield Management opened a new position in AbbVie worth $89.8M.

  • Deerfield Management's largest Q1 2015 buy was AbbVie: 1,534,000 shares worth $89.8M.
  • Deerfield Management added most to AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q1 2015, an estimated $99.9M increase.
  • Deerfield Management's biggest Q1 2015 reduction was Aerie Pharmaceuticals, cutting an estimated $36.3M.
  • Deerfield Management fully exited AUXILIUM PHARAMCEUTICALS INC in Q1 2015, selling an estimated $216M.
  • Deerfield Management's ten largest holdings make up 47% of its $3.09B portfolio in Q1 2015.
  • Deerfield Management opened 43 new positions and closed 29 in Q1 2015.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $3.09B.

Based on Deerfield Management's 13F filing for Q1 2015, filed 15 May 2015.